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Abstract: We examined anti-tumor effects of the Traditional Chinese Medicine (TCM), Ekki-Youketsu-Fusei-Zai 
(EYFZ), on survival, tumor size, body weight, and natural killer (NK) cell activity in tumor-bearing mice by using 
a tumor cell line, colon-26. The significant life-prolonging effect was found, when EYFZ was orally administrated 
for 28 days, which procedure started just after the subcutaneous implantation of colon-26 cell line. In addition, an 
oral administration of EYFZ inhibited the tumor growth and the loss of body weight in tumor-bearing mice. The 
significant increases in splenic NK cell activity of the tumor-bearing mice were also induced by oral administration 
of EYFZ. These results strongly suggest that EYFZ has the anti-tumor effects on colon-26 implanted mice via 
augmentation of NK cell activity.
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Introduction
Some kinds of crude drugs of Traditional Chinese 
Medicine (TCM) have been so far useful for cancer 
patients as both an anti-tumor drug and an adjuvant, 
which greatly enhances the immunological functions 
of cancer patients1, 2). Ekki-Youketsu-Fusei-Zai (EYFZ), 
one of the TCMs, is a mixture composed of six kinds of 
crude drugs, which have been used for cancer patients 
in China. Recent studies have shown that each crude 
drug has various biological activities. For example, 
Astragali radix has immunologically enhancing and 
anti-tumor effects3-5), while Angelicae radix has anti-
inflammatory, analgesic, interferon inducing, and 
immunopotentiating effects6-9). Cervi parvum cornu 
is known to show anti-tumor and immuno-enhancing 
effects by inhibiting the monoamine oxidase (MAO) 
activity10-12), and Zizyphi fructus augments the function 
of natural killer cell as well as ciliary motility in 
the airway13, 14). Finally, Rehmanniae radix is reported 
to have anti-tumor activity, enhance cytotoxic T 
lymphocytes (CTL) activity and induce IL-2 production 
by T cells15, 16).
Though each component of EYFZ has shown 
various biological activities and EYFZ has been used 
for cancer patients, its anti-tumor effects and immuno-
enhancing effects have not been investigated. In this 
study, we examined the effects of oral administration 
of EYFZ on the survival, tumor size, body weight and 
natural killer (NK) cell activity of tumor-bearing mice 
in order to elucidate the relationship between immuno-
enhancing effects of EYFZ and its anti-tumor effects.
Materials and Methods
Animals and tumor cell line Specific-pathogen-free 
BALB/c female mice at the age of 5 weeks, originally 
purchased from Japan CLEA Co, were used throughout 
this experiment and approved by institutional animal care 
committee. Colon-26 cell line, colon-adenocarcinoma 
from BALB/c mice, was generously provided by Prof. 
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Kikuo Nomoto, Kyushu University, and cultured in 
vitro with the basal medium (RPMI-1640) containing 
10 % fetal bovine serum (FBS), 2.0 g/L NaHCO3 , 
1.0 g/L HEPES, 0.6 g/L L-glutamine, and 0.25 mg/L 
Kanamycin. By a strong pipetting procedure, we 
obtained a single cell suspension and 5105 cells were 
implanted subcutaneously into the back of mouse. 
Murine lymphoma YAC-1 cell was maintained in the 
same culture medium as shown above.
Preparation of EYFZ EYFZ is a mixture composed 
of six kinds of crude drugs as shown in Table 1. All 
of the crude drugs were obtained from Tochimoto, 
Ltd., Osaka, and EYFZ was prepared as follows. First, 
a mixture of Astragali radix (10.0 g), Zizyphy fructus 
(5.0 g), Amomi semen (5.0 g), Angelicae radix (8.0 g), 
Cerve parvum cornu (5.0 g), and Rehamnniiae radix 
(10.0 g) was added to 200 ml water and soaked for 20 
min. Then, it was boiled for 30 min for extraction of 
effective substances, and filtered. Finally, the extracted 
solution was condensed to 43 ml (1 g crude drug/ml) 
by heating evaporation, and orally administered to mice 
at a dose of 716.7 mg crude drug/kg. This dose was 
considered appropriate because oral administration of 
EYFZ into human is traditionally 43 g crude drug/60 
kg/day.
Evaluation of survival, tumor size, and body 
weight of tumor-bearing mice Colon-26 (5  105 ) cells 
were subcutaneously implanted into 6-week-old mouse 
at once, and simultaneously the oral administration of 
EYFZ was started. Control mice received the same 
volume of saline instead of EYFZ. Thereafter, the 
survival of these mice was monitored everyday for 
evaluating the life-prolonging effect. The tumor size and 
body weight were examined 2-3 times a week. The major 
axis (a) and minor axis (b) of the tumor were measured, 
size was estimated by using the formula ab2/217).
Assay of splenic NK cell activity The splenic NK 
cell activity of tumor-bearing mice was determined by 
lactate dehydrogenase (LDH) assay18, 19). The spleen cell 
suspension was prepared by squeezing the spleen between 
two glass slides. The distilled water was added to the 
spleen cell suspension for provoking lysis of red blood 
cells. After washing three times with serum-free basal 
medium, the cells were incubated in a 25 cm2 culture flask 
(FALCON, Becton Dickinson) in serum-free basal medium 
at 37 ℃ in a 5 % CO2 incubator for 2hr to remove adherent 
cells. The non-adherent cells were collected as effector 
cells. Effector cells (5106 cells/ml) were incubated with 
NK-sensitive target cells, YAC-1 (5104 cells/ml), in a 
total volume of 0.2 ml/well using 96 well round bottomed 
microplate (IWAKI Glass Co, Ltd.). An effector-target ratio 
of 100:1 was considered optimum. The plate was incubated 
for 4 hr at 37 ℃ in a 5 % CO2 incubator. After incubation, 
0.05 ml of the supernatant from each well was collected, 
then used for LDH assay to determine the cytotoxic 
activity using the LDH cytotoxic Kit (Wako Pure Chemical 
Industries, Ltd.). The percentage of specific release was 
calculated according to the following formula: % specific 
lytic activity  (experiment release - spontaneous release) 
/ (maximum release - spontaneous release)  100.
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Statistical analysis Survival curve was determined 
using the method of Kaplan and Meier, and the log rank 
test was used to calculate the significance. Other data 
were statistically analyzed based on the Student’s t test, 
and the differences were recognized significant with 
p value less than 0.05. The results were expressed as 
mean  standard deviation (SD).
Results 
We first examined the effect of oral administration 
of EYFZ on the survival of tumor-bearing mice. When 
EYFZ (716.7 mg crude drug/kg/day) was continuously 
administrated to the mice which had been implanted 
subcutaneously with colon-26 for 28 days, the life-prolonging 
effect was found as shown in Fig. 1. All of tumor-bearing 
mice in the control group that received only the saline died 
within 59 days after the onset of this experiment (Fig. 1). On 
the other hand, the tumor-bearing mice treated with EYFZ 
showed a significant life-prolonging effect as compared to 
the control (p0.01), and died in 70 days on average.
Secondly, we compared the tumor size of EYFZ-
administered group mice with that of control group mice. 
The tumor size, as described in Materials and Methods, 
was calculated by measuring the major (a) and minor (b) 
axis of formed tumor tissue based on the formula ab2/2. 
Result obtained from observation for 34 days revealed that 
the tumor size in EYFZ-administrated mice was smaller 
than that in the control mice (Fig. 2). Although the tumor 
size on day-13 was almost similar to that in the control, 
those on day-20 and on day-27 were clearly smaller than that 
in the control group (p0.5 and p0.1, respectively).
Thirdly, we examined the effect of oral administration 
of EYFZ on the body weight in tumor-bearing mice. 
When we observed the body weight of mice in the EYFZ-
treated or control mice successively for 28 days after 
the onset of this experiment, it was shown that the body 
weight in the EYFZ-treated mice was much larger than 
that in the control mice (Fig. 3). Particularly, the body 
weight in the treated mice was significantly larger than 
that in the control mice on day-14 (p0.05).
Finally, we examined the effect of oral administration 
of EYFZ on splenic NK cell cytotoxicity in tumor-bearing 
mice. We found that the NK cytotoxic activity of splenic 
cells in orally EYFZ-administrated mice was significantly 
higher than that in control mice on the day-17 and day-24 
after the onset of transplantation and oral administration, 
as shown in Fig. 4 (p0.01).
Discussion
In this experiment, we examined whether EYFZ, one 
of the TCMs, affected the anti-tumor activity in mice 
into which the murine colon-26 carcinoma cell line was 
subcutaneously implanted. This colon-26 cell line, an 
undifferentiated carcinoma induced by the carcinogen 
N-nitroso-N-methylurethan, has been successfully used 
as the model of tumor-bearing mice and cachexia17, 20). 
In our study, colon-26 cells could grow well after 
subcutaneous implantation into the normal BALB/c 
mice. Oral administration of EYFZ caused a statistically 
significant prolonging effect on survival in tumor-bearing 
mice as compared with the control mice. We also 
examined both the tumor size and body weight. The 
tumor size in EYFZ-administrated mice was shown 
to be much more decreased than that in the control 
mice. Particularly, the tumor size in the treated mice 
after 27 days became significantly smaller than that 
in the control. Hence, it is suggested that the oral 
administration of EYFZ was more effective compared 
with oral administration of saline for both the survival 
and the decrease of a tumor size in tumor-bearing mice.
The cachexia, an exhaustive state with severe weight 
loss, is a serious problem in cancer patients affecting 
their morbidity and mortality. It lowers their quality 
of life and shortens their life-span21, 22). Colon-26 cell 
line has been successfully used as the model of such 
cachexia by tumor growth17). Thus, we observed the 
body weight of tumor-bearing mice everyday following 
the subcutaneous implantation of colon-26 cells into both 
the EYFZ-treated and the control mice. Results clearly 
showed that oral administration of EYFZ led to the better 
increase of body weight as compared to the control 
without EYFZ. Though the body weight of the control 
mice was lower than that of the EYFZ-treated mice, 
initially, it finally reached the similar level to that of the 
EYFZ-treated mice. This means the tumor growth in the 
control mice leads to the increase of body weight. We 
think the difference of the body weight between two 
groups of mice on day-14 is much more important that 
on the later days, and it reflects improvement of cachexia 
by EYFZ. However, since there was a possibility that 
EYFZ influenced the increase of the body weight of 
cancer-bearing mice from the nutritious viewpoints, it 
will be necesarry to further examine the effect of oral-
administration of EYFZ on the body weight of the normal 
mice without cancer cell in the future.
NK cells exhibit spontaneous cytotoxic activity in a 
non-major histocompatibilty complex (MHC) restricted 
manner against virus-infected cells and cancer cells 
in vivo and their activity can be augmented by 
administration of interferon-  (IFN- )21-24). Some papers 
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Fig. 1. Effect of Ekki-Youketsu-Fusei-Zai (EYFZ) on survival of mice inoculated with colon-26 cells. Six 
BALB/c female mice per group were inoculated s.c with colon-26 (5105 cells/mouse). Treatment group 
mice were orally administered with EYFZ (716.7 mg crude drug/kg) for 28 days just after the subcutaneous 
implantation of colon-26 cell line. The control group mice received only saline. Their survival rates are shown. 
(): treatment group mice, (): control group mice. P0.01; by log rank test.
Fig. 2. Effect of Ekki-Youketsu-Fusei-Zai (EYFZ) on the in vivo growth of colon-26 tumor cells. Mice treated 
with EYFZ (716.7 mg crude drug/kg) and control mice without EYFZ were inoculated with colon-26 cells 
according to the same protocol as in Fig. 1. Tumor growth was measured after implantation and calculated as 
shown in Material and Methods. The tumor size was measured from day-9 to day-34 after transplantation. (): 
treatment group mice, (): control group mice.
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Fig. 3. Effect of Ekki-Youketsu-Fusei-Zai (EYFZ) on body weight loss of mice inoculated with colon-26 cells. 
Mice treated with EYFZ (716.7 mg crude drug/kg) and control mice without EYFZ were inoculated with 
colon-26 cells according to the same protocol as in Fig. 1. After implantation, the body weight was measured 
2 or 3 times a week and finally on day-28. (): treatment group mice, (): control group mice.
Fig. 4. Effect of Ekki-Youketsu-Fusei-Zai (EYFZ) on NK cell activity of mice inoculated with colon-26 
cells. Five BALB/c female mice per group were inoculated s.c with colon-26 cells (5105 cells/mouse). 
Treatment group mice were orally administered with EYFZ (716.7 mg crude drug/kg) for 28 days just after 
the subcutaneous implantation of colon-26 cell line. Control group mice received only saline. Each column 
and vertical bar represents the meanstandard deviation of 5 mice on day-10, day-17, day-24 and day-31 after 
inoculation.  (): treatment group mice, (): control group mice. *P0.5 and **P0.01; by Student’s two-
tailed test. 
showed that some kinds of crude drugs and TCMs 
exert anti-tumor effects by activation of NK cells13, 25-29). 
Therefore, we also tried to examine the cytotoxic effect 
of oral administration of EYFZ on splenic NK cell 
activity in tumor-bearing mice on day-10, day-17, day-24 
and day-31 following the subcutaneous implantation 
of colon-26 cells. Results clearly showed that the NK 
activity of spleen cells in orally EYFZ-administrated 
mice was significantly higher than that in control 
mice on the day-17 and day-24 after transplantation 
and oral EYFZ administration. Those results suggest 
the possibility that EYFZ has the anti-tumor effect 
on colon-26 implanted mice via augmentation of NK 
cell activity. In our present experiment, it was hard 
to investigate the cytokine production of NK cells in 
the spleen due to the insufficient number of splenic 
NK cells. However, as the NK activity was clearly 
augmented in the EYFZ-treated mice, further evaluation 
for EYFZ in anti-tumor activity seems to be needed by 
examining the effect of oral-administration of EYFZ on 
the cytokine production of NK cells in the spleen. 
EYFZ does not show the direct cytotoxicity on some 
tumor cell lines including colon-26, A549 and Kato III 
(data not shown). This greatly suggests that the efficacy 
of EYFZ on survival and tumor-growth in tumor-bearing 
mice is attributable to the enhancement of host defense 
or immune system such as NK cell activity but not to 
the direct cytotoxicity against tumor cells. The efficacy 
of biological response modifier (BRM) in cancer therapy 
has been attributed to its activating functions on immune 
system including neutrophils, macrophages, NK cells, 
and cytotoxic T cells as well as on various cytokines. 
Therefore, it would be important to investigate further 
the effect of EYFZ on the immune system. This point is 
currently being pursued in detail in our laboratory.
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中国の伝統的漢方薬である「益気養血扶正剤」（オ
ウギ，ジュクジオウ，トウキ，ジュクシャ，タイソウ，
ロクジョウの６種類から構成される：以下EYFZと略
す）の抗腫瘍活性と免疫細胞機能に及ぼす影響を知る
目的で，第 1にcolon-26腫瘍細胞株を移植した担癌マ
ウス（BALB/c）を用いて，28日間のEYFZ経口投与が
担癌マウスの延命とNK細胞機能にいかなる影響を与
えるかについて追究した．実験の結果，EYFZを連続
的に投与された担癌マウスの寿命は非投与群と比較し
て有意に延命することがわかった．特にEYFZの経口
投与によって，腫瘍サイズと体重の減少が抑制され
た．一方，担癌マウスの脾臓細胞を採取して，その中
のNK活性を知るためYAC-1細胞への細胞傷害活性を
LDH（lactate dehydrogenase）アッセイによって調べ
た結果，EYFZを投与された担癌マウスでは，非投与
群と比較して有意にNK活性が高まることが判明した．
これらの結果から，EYFZにはcolon-26を移植された
担癌マウスの延命を引き起こす抗腫瘍効果があり，そ
の作用機構の一つにNK活性の亢進のあることが示唆
された．
中国の伝統的漢方薬「益気養血扶正剤」の抗腫瘍活性と免疫細胞機能に及ぼす影響
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